创纪录！恒瑞医药2025半年报：净利44.50亿元，飙升29.67%

Core Viewpoint - Heng Rui Medicine reported significant growth in revenue, net profit, and operating cash flow for the first half of 2025, indicating a period of explosive growth for the company [1] Financial Performance - The company achieved operating revenue of 15.76 billion yuan, representing a year-on-year increase of 15.88% [1] - Net profit attributable to shareholders reached 4.45 billion yuan, with a year-on-year growth of 29.67% [1] - Operating cash flow net amount was 4.30 billion yuan, showing a year-on-year increase of 41.80% [1] - All key financial metrics reached record highs for the same period in previous years, marking a significant performance milestone [1] Research and Development - The company has increased its focus on innovation, maintaining a high level of investment in research and development [1] - Total R&D expenditure during the reporting period was 3.87 billion yuan, with 3.23 billion yuan classified as expensed R&D [1]